NCT04238364View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

December 16, 2021

Study Completion Date

January 10, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

EI-1071

EI-1071 Tablet(s)

DRUG

Placebo

Matching Placebo Tablet(s)

Trial Locations (1)

21225

Parexel Early Phase Clinical Unit, Baltimore

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Elixiron Immunotherapeutics (Hong Kong) Ltd.

INDUSTRY